´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : ´ç´¢º´¼º ¸Á¸·Áõ À¯Çüº°, Ä¡·á À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº°-»ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Diabetic Retinopathy Therapeutic Market, By Diabetic Retinopathy Type, By Treatment Type, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå
:
1606457
¸®¼Ä¡»ç
:
AnalystView Market Insights
¹ßÇàÀÏ
:
2024³â 11¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 303 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
º¸°í¼ ÇÏÀ̶óÀÌÆ®
´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2023³â 91¾ï 932¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 6.88%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.
´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå-½ÃÀå ¿ªÇÐ
´ç´¢º´ ¹× ´ç´¢º´¼º ¸Á¸·ÁõÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ö¿ä ÃËÁø
¼¼°è ´ç´¢º´ ÀÌȯÀ² »ó½ÂÀ¸·Î ´ç´¢º´¼º ¸Á¸·ÁõÀÌ ¹ßº´ÇÏ´Â »ç¶÷ÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æ°ü¸®¼¾ÅÍ(CDC)¿¡ µû¸£¸é 2021³â¿¡´Â ¹Ì±¹ÀÇ ¸ðµç ¿¬·ÉÃþ¿¡¼ ÃßÁ¤ 960¸¸ ¸íÀÌ ´ç´¢º´¼º ¸Á¸·º´ÁõÀÌ ¹ßº´Çß½À´Ï´Ù. ±×·¯³ª Ä¡·á ·¹Áö¸àÀÇ º¹À⼺À̳ª Ä¡·áÀÇ ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀº ȯÀÚ°¡ 󹿹ÞÀº Ä¡·á °èȹÀ» Áöų ÀÇ¿åÀ» ÀÒ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×¿Í ¹Ý´ë·Î ´ç´¢º´¼º ¸Á¸·Áõ °ü¸®¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ Á¶»ç¿Í ±â¼úÀÇ Áøº¸´Â ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ´õ¿íÀÌ ´ç´¢º´ ȯÀÚÀÇ Á¤±âÀûÀÎ ¾È°ú °ËÁøÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÇ °íÁ¶´Â ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ °¡Á®¿É´Ï´Ù.
´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå-ÁÖ¿ä ÀλçÀÌÆ®
¿ì¸®ÀÇ ¸®¼Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 6.88%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
´ç´¢º´¼º ¸Á¸·Áõ À¯Çüº°·Î, ºñÁõ½Ä ´ç´¢º´¼º ¸Á¸·ÁõÀº 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» ³ªÅ¸³½ °ÍÀ¸·Î Æò°¡µË´Ï´Ù.
Ä¡·á À¯Çüº°·Î, 2023³â¿¡ Ç×Ç÷°ü³»ÇǼºÀåÀÎÀÚ(VGEF) ¾à¹°ÀÌ ÁÖ¿ä ºÎ¹®À̾ú½À´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹ÌÀÇ ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀåÀÌ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.
´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå-¼¼ºÐÈ ºÐ¼® :
¼¼°èÀÇ ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀåÀº ´ç´¢º´¼º ¸Á¸·Áõ À¯Çüº°, Ä¡·á À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº° ¹× Áö¿ªº°·Î ¼¼ºÐȵ˴ϴÙ.
´ç´¢º´¼º ¸Á¸·Áõ À¯Çüº°·Î´Â Áõ½Ä ´ç´¢º´¼º ¸Á¸·Áõ°ú ºñÁõ½Ä ´ç´¢º´¼º ¸Á¸·ÁõÀÇ µÎ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ºñÁõ½Ä ´ç´¢º´¼º ¸Á¸·Áõ ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÁÖ·Î ´ç´¢º´ ȯÀÚÀÇ ³ôÀº À¯º´·ü, Á¶±â ¹ß°ß ¹× Ä¡·á ¿É¼ÇÀÇ ÀÎÁöµµ¿Í ÀÔ¼ö °¡´É¼º Çâ»ó¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù.
½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚº°·Î ¾È°ú¼¾ÅÍ, º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ, ±âŸ µî 4°¡Áö·Î ºÐ·ùµË´Ï´Ù. º´¿ø ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ¾î ¿¹Ãø ±â°£ Áß¿¡µµ ±× ¿ìÀ§¼ºÀº À¯ÁöµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ¿ìÀ§¼ºÀº ÁÖ·Î ´ç´¢º´¼º ¸Á¸·ÁõÀ» È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇØ ÇʼöÀûÀÎ °íµµÀÇ Áø´Ü µµ±¸¿Í ¿Ü°úÀû °³ÀÔÀ» Æ÷ÇÔÇÑ Æ÷°ýÀûÀÎ Äɾ Á¦°øÇÏ´Â º´¿øÀÇ ´É·Â¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù.
´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå-Áö¸®Àû ÀλçÀÌÆ®
Áö¸®ÀûÀ¸·Î, ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °¢ Áö¿ªÀ¸·Î ÆÛÁ® ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¿ªÀº ºñÁî´Ï½º¸¦ ¼±µµÇÏ´Â ±¹°¡¿¡ µû¶ó ´õ ³ª´¹´Ï´Ù.
´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå-°æÀï ±¸µµ :
´ç´¢º´¼º ¸Á¸·ÁõÀÇ À¯º´·ü Áõ°¡´Â Çõ½ÅÀûÀÎ Ä¡·á Àü·«°ú Á¾ÇÕÀûÀΠȯÀÚ Äɾ ´ëÇÑ ÁÖ·ÂÀ» Ư¡À¸·Î ÇÏ´Â °æÀï ±¸µµ¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ±â¾÷Àº ¿ø°ÝÀǷᳪ µðÁöÅÐ Çコ ¼Ö·ç¼Ç µîÀÇ ¼±Áø ±â¼úÀ» Ȱ¿ëÇØ, ȯÀÚÀÇ ÀΰÔÀÌÁö¸ÕÆ®¸¦ ³ô¿©, Ä¡·á¿¡ ´ëÇÑ ¾×¼¼½º¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ´ç´¢º´¼º ¸Á¸·ÁõÀÇ ´Ù¾çÇÑ º´±â¸¦ Ÿ°ÙÀ¸·Î ÇÏ´Â ½Å±Ô Ä¡·á¹ýÀ» µµÀÔÇϱâ À§ÇØ, ¸¹Àº Á¶Á÷ÀÌ ¿¬±¸ °³¹ßÀ» ¿ì¼±ÇØ, ¾È¸ÞÆ® ¸ÞµðÄà ¿ä±¸¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ÇコÄɾî Á¦°ø¾÷ü³ª ¿¬±¸±â°ü°úÀÇ Á¦ÈÞ³ª ÆÄÆ®³Ê½Êµµ ÀϹÝÀûÀÎ Àü·«À̸ç, À̸¦ ÅëÇØ ±â¾÷Àº ½ÃÀåÀ¸·ÎÀÇ ¸®Ä¡¸¦ È®´ëÇϰí Ä¡·á ¼º°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå °³¿ä
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·áÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
½ÃÀå ±âȸ
½ÃÀåÀÇ ¹Ì·¡ µ¿Çâ
Á¦4Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á »ê¾÷ ¿¬±¸
PEST ºÐ¼®
Porter's Five Forces ºÐ¼®
¼ºÀå Àü¸Á ¸ÊÇÎ
±ÔÁ¦ Ʋ ºÐ¼®
Á¦5Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ
COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ
·¯½Ã¾Æ¿Í ¿ìÅ©¶óÀ̳ª ÀüÀïÀÇ ¿µÇâ
Áßµ¿ ºÐÀïÀÇ ¿µÇâ
Á¦6Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå »óȲ
´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
ÁÖ¿ä Á¦Á¶¾÷üº° ºÐ¼® µ¥ÀÌÅÍ
±âÁ¸ ±â¾÷ÀÇ ºÐ¼®
½ÅÈï ±â¾÷ÀÇ ºÐ¼®
Á¦7Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : ´ç´¢º´¼º ¸Á¸·Áõ À¯Çüº°
°³¿ä
´ç´¢º´¼º ¸Á¸·Áõ À¯Çüº° : ºÎ¹® Á¡À¯À² ºÐ¼®
Áõ½Ä¼º ´ç´¢º´¼º ¸Á¸·Áõ
ºñÁõ½Ä¼º ´ç´¢º´¼º ¸Á¸·Áõ
Á¦8Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°
°³¿ä
Ä¡·á À¯Çüº° : ºÎ¹® Á¡À¯À² ºÐ¼®
·¹ÀÌÀú ¼ö¼ú
Ç×Ç÷°ü ³»ÇÇ Áõ½Ä ÀÎÀÚ(VEGF) ¾à
¾È³» ½ºÅ×·ÎÀ̵å ÁÖ»ç
À¯¸®Ã¼ ÀýÁ¦¼ú
Á¦9Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°
°³¿ä
ÃÖÁ¾ »ç¿ëÀÚº° : ºÎ¹® Á¡À¯À² ºÐ¼®
¾È°ú ºÐ¾ß
º´¿ø
¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
±âŸ
Á¦10Àå ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ½ÃÀå : Áö¿ª
¼¹®
ºÏ¹Ì
°³¿ä
ºÏ¹ÌÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
¹Ì±¹
ij³ª´Ù
À¯·´
°³¿ä
À¯·´ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
µ¶ÀÏ
ÀÌÅ»¸®¾Æ
¿µ±¹
ÇÁ¶û½º
·¯½Ã¾Æ
³×´ú¶õµå
½º¿þµ§
Æú¶õµå
±âŸ
¾Æ½Ã¾ÆÅÂÆò¾ç
°³¿ä
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
Àεµ
Áß±¹
ÀϺ»
Çѱ¹
È£ÁÖ
ű¹
Àεµ³×½Ã¾Æ
Çʸ®ÇÉ
±âŸ
¶óƾ¾Æ¸Þ¸®Ä«
°³¿ä
¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
ºê¶óÁú
¸ß½ÃÄÚ
¾Æ¸£ÇîÆ¼³ª
ÄÝ·Òºñ¾Æ
±âŸ
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
°³¿ä
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
À̽º¶ó¿¤
ÅÍŰ
¾ËÁ¦¸®
ÀÌÁýÆ®
±âŸ
Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·á ¾÷°è
°æÀï ´ë½Ãº¸µå
°æÀï º¥Ä¡¸¶Å·
°æÀï Æ÷Áö¼Å´×
±â¾÷ ÇÁ·ÎÆÄÀÏ
F. Hoffmann-La Roche Ltd.
Abbott
Alimera Sciences
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Bayer AG
Oxurion NV
ABBVIE INC.
Sirnaomics
Ampio Pharmaceuticals Inc.
BCNPeptides
Genentech, Inc.
Kowa Company Ltd.
Aurobindo Pharma
Bausch Health Companies Inc.
Accord Healthcare
Regeneron Pharmaceuticals Inc.
Lumenis Be Ltd.
Glycadia, Inc.
Others
Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á
AJY
¿µ¹® ¸ñÂ÷
REPORT HIGHLIGHT
Diabetic retinopathy therapeutic market size was valued at USD 9,109.32 Million in 2023, expanding at a CAGR of 6.88% from 2024 to 2032.
Diabetic retinopathy is a serious eye condition stemming from complications related to diabetes mellitus and is a leading cause of blindness worldwide. The severity of diabetic retinopathy depends on several factors, including the type of diabetes, the duration of the disease, and how well blood sugar levels are managed. Early symptoms may be minimal or even absent, but as the condition progresses, individuals can experience blurred vision, fluctuating eyesight, and impaired color perception, potentially leading to blindness if not addressed.
Diabetic Retinopathy Therapeutic Market- Market Dynamics
Increasing prevalence of diabetes and diabetic retinopathy to propel market demand
The rising incidence of diabetes globally has led to a higher number of individuals developing diabetic retinopathy. According to Centers for Disease Control and Prevention (CDC), an estimated 9.6 million people across all ages in the US were living with diabetic retinopathy in 2021.However, the complexity of treatment regimens and the potential side effects of therapies can discourage patients from adhering to their prescribed treatment plans. On the contrary, ongoing research and technological advancements in the management of diabetic retinopathy are expected to boost market growth. Furthermore, Increased awareness about the importance of regular eye examinations for diabetes patients presents an opportunity for growth in the diabetic retinopathy therapeutic market.
Diabetic Retinopathy Therapeutic Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.88% over the forecast period (2024-2032)
Based on diabetic retinopathy type segmentation, non-proliferative diabetic retinopathy was predicted to show maximum market share in the year 2023
Based on treatment type segmentation, anti-vascular endothelial growth factor (VGEF) drug was the leading segment in 2023
On the basis of region, The North America diabetic retinopathy therapeutic market was the leading revenue generator in 2023
Diabetic Retinopathy Therapeutic Market- Segmentation Analysis:
The Global Diabetic Retinopathy Therapeutic Market is segmented on the basis of Diabetic Retinopathy Type, Treatment Type, End user, and Region.
The market is divided into two categories based on diabetic retinopathy type: proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy sector dominates the market. This is mainly due to its higher prevalence among diabetic patients and the increasing awareness and availability of early detection and treatment options.
The market is divided into four categories based on end user: ophthalmic centers, hospitals, ambulatory surgery centers, and others. The hospitals sector dominates the market and is likely to maintain its dominance during the forecast period. This dominance is primarily driven by hospitals' ability to provide comprehensive care, including advanced diagnostic tools and surgical interventions, which are crucial for managing diabetic retinopathy effectively.
Diabetic Retinopathy Therapeutic Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
Diabetic Retinopathy Therapeutic Market- Competitive Landscape:
The increasing prevalence of diabetic retinopathy is driving a competitive landscape characterized by innovative treatment strategies and a focus on comprehensive patient care. Companies are leveraging advanced technologies, such as telemedicine and digital health solutions, to enhance patient engagement and improve access to care. Additionally, many organizations are prioritizing research and development to introduce novel therapies that target various stages of diabetic retinopathy, thereby addressing unmet medical needs. Collaboration and partnerships with healthcare providers and research institutions are also common strategies, enabling companies to expand their market reach and improve treatment outcomes.
Recent Developments:
In April 2024, Ocular Therapeutix, Inc. announced promising topline results from its Phase 1 HELIOS study, which investigated AXPAXLI against a sham control in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME). The study's positive findings highlight Ocular's commitment to developing innovative therapies for conditions like wet age-related macular degeneration and diabetic retinopathy.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
F. Hoffmann-La Roche Ltd.
Abbott
Alimera Sciences
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Bayer AG
Oxurion NV
ABBVIE INC.
Sirnaomics
Ampio Pharmaceuticals Inc.
BCNPeptides
Genentech, Inc.
Kowa Company Ltd.
Aurobindo Pharma
Bausch Health Companies Inc.
Accord Healthcare
Regeneron Pharmaceuticals Inc.
Lumenis Be Ltd.
Glycadia, Inc.
Others
GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY DIABETIC RETINOPATHY TYPE- MARKET ANALYSIS, 2019 - 2032
Proliferative Diabetic Retinopathy
Non-proliferative Diabetic Retinopathy
GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032
Laser Surgery
Anti-vascular Endothelial Growth Factor (VEGF) Drug
Intraocular Steroid Injection
Vitrectomy
GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
Ophthalmic Centers
Hospitals
Ambulatory Surgery Centers
Others
GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA
Table of Contents
1. Diabetic Retinopathy Therapeutic Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Diabetic Retinopathy Therapeutic Market Snippet by Diabetic Retinopathy Type
2.1.2. Diabetic Retinopathy Therapeutic Market Snippet by Treatment Type
2.1.3. Diabetic Retinopathy Therapeutic Market Snippet by End User
2.1.4. Diabetic Retinopathy Therapeutic Market Snippet by Country
2.1.5. Diabetic Retinopathy Therapeutic Market Snippet by Region
2.2. Competitive Insights
3. Diabetic Retinopathy Therapeutic Key Market Trends
3.1. Diabetic Retinopathy Therapeutic Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Diabetic Retinopathy Therapeutic Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Diabetic Retinopathy Therapeutic Market Opportunities
3.4. Diabetic Retinopathy Therapeutic Market Future Trends
4. Diabetic Retinopathy Therapeutic Industry Study
4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Diabetic Retinopathy Therapeutic Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Diabetic Retinopathy Therapeutic Market Landscape
6.1. Diabetic Retinopathy Therapeutic Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players' Analysis
6.2.2. Emerging Players' Analysis
7. Diabetic Retinopathy Therapeutic Market - By Diabetic Retinopathy Type
7.1. Overview
7.1.1. Segment Share Analysis, By Diabetic Retinopathy Type, 2023 & 2032 (%)
7.1.2. Proliferative Diabetic Retinopathy
7.1.3. Non-proliferative Diabetic Retinopathy
8. Diabetic Retinopathy Therapeutic Market - By Treatment Type
8.1. Overview
8.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
8.1.2. Laser Surgery
8.1.3. Anti-vascular Endothelial Growth Factor (VEGF) Drug
8.1.4. Intraocular Steroid Injection
8.1.5. Vitrectomy
9. Diabetic Retinopathy Therapeutic Market - By End User
9.1. Overview
9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
9.1.2. Ophthalmic Centers
9.1.3. Hospitals
9.1.4. Ambulatory Surgery Centers
9.1.5. Others
10. Diabetic Retinopathy Therapeutic Market- By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Diabetic Retinopathy Therapeutic Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Diabetic Retinopathy Therapeutic Industry
11.1. Competitive Dashboard
11.1.1. Competitive Benchmarking
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. F. Hoffmann-La Roche Ltd.
11.2.2. Abbott
11.2.3. Alimera Sciences
11.2.4. Novartis AG
11.2.5. Pfizer Inc.
11.2.6. Regeneron Pharmaceuticals, Inc.
11.2.7. Bayer AG
11.2.8. Oxurion NV
11.2.9. ABBVIE INC.
11.2.10. Sirnaomics
11.2.11. Ampio Pharmaceuticals Inc.
11.2.12. BCNPeptides
11.2.13. Genentech, Inc.
11.2.14. Kowa Company Ltd.
11.2.15. Aurobindo Pharma
11.2.16. Bausch Health Companies Inc.
11.2.17. Accord Healthcare
11.2.18. Regeneron Pharmaceuticals Inc.
11.2.19. Lumenis Be Ltd.
11.2.20. Glycadia, Inc.
11.2.21. Others
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
°ü·ÃÀÚ·á